TY - JOUR
T1 - Roadmap for a precision-medicine initiative in the Nordic region
AU - Njølstad, Pål Rasmus
AU - Andreassen, Ole Andreas
AU - Brunak, Søren
AU - Børglum, Anders D
AU - Dillner, Joakim
AU - Esko, Tõnu
AU - Franks, Paul W
AU - Freimer, Nelson
AU - Groop, Leif
AU - Heimer, Hakon
AU - Hougaard, David M
AU - Hovig, Eivind
AU - Hveem, Kristian
AU - Jalanko, Anu
AU - Kaprio, Jaakko
AU - Knudsen, Gun Peggy
AU - Melbye, Mads
AU - Metspalu, Andres
AU - Mortensen, Preben Bo
AU - Palmgren, Juni
AU - Palotie, Aarno
AU - Reed, Wenche
AU - Stefánsson, Hreinn
AU - Stitziel, Nathan O
AU - Sullivan, Patrick F
AU - Thorsteinsdóttir, Unnur
AU - Vaudel, Marc
AU - Vuorio, Eero
AU - Werge, Thomas
AU - Stoltenberg, Camilla
AU - Stefánsson, Kári
PY - 2019/6/1
Y1 - 2019/6/1
N2 - The Nordic region, comprising primarily Denmark, Estonia, Finland, Iceland, Norway and Sweden, has many of the necessary characteristics for being at the forefront of genome-based precision medicine. These include egalitarian and universal healthcare, expertly curated patient and population registries, biobanks, large population-based prospective cohorts linked to registries and biobanks, and a widely embraced sense of social responsibility that motivates public engagement in biomedical research. However, genome-based precision medicine can be achieved only through coordinated action involving all actors in the healthcare sector. Now is an opportune time to organize scientists in the Nordic region, together with other stakeholders including patient representatives, governments, pharmaceutical companies, academic institutions and funding agencies, to initiate a Nordic Precision Medicine Initiative. We present a roadmap for how this organization can be created. The Initiative should facilitate research, clinical trials and knowledge transfer to meet regional and global health challenges.
AB - The Nordic region, comprising primarily Denmark, Estonia, Finland, Iceland, Norway and Sweden, has many of the necessary characteristics for being at the forefront of genome-based precision medicine. These include egalitarian and universal healthcare, expertly curated patient and population registries, biobanks, large population-based prospective cohorts linked to registries and biobanks, and a widely embraced sense of social responsibility that motivates public engagement in biomedical research. However, genome-based precision medicine can be achieved only through coordinated action involving all actors in the healthcare sector. Now is an opportune time to organize scientists in the Nordic region, together with other stakeholders including patient representatives, governments, pharmaceutical companies, academic institutions and funding agencies, to initiate a Nordic Precision Medicine Initiative. We present a roadmap for how this organization can be created. The Initiative should facilitate research, clinical trials and knowledge transfer to meet regional and global health challenges.
U2 - 10.1038/s41588-019-0391-1
DO - 10.1038/s41588-019-0391-1
M3 - Comment/debate
C2 - 30988515
SN - 1061-4036
VL - 51
SP - 924
EP - 930
JO - Nature Genetics
JF - Nature Genetics
ER -